Acyvir IV Infusion 500 mg/vial

Acyvir IV Infusion, manufactured by Aristopharma Ltd, is a potent antiviral formulation containing 500 mg/vial of Acyclovir. Priced at ৳700.00 per vial, this IV Infusion effectively treats severe herpes infections. It is recommended for immunocompromised patients and those with acute viral manifestations requiring systemic therapy.

This medication targets Herpes simplex and Varicella-zoster viruses by inhibiting viral DNA replication. Its active metabolite, Acyclovir Triphosphate, disrupts viral enzymes more effectively than human DNA polymerase, ensuring selective toxicity. Clinical indications include encephalitis, shingles, and genital herpes with severe systemic involvement.

Dosage varies between 5-10 mg/kg administered every 8 hours, infused intravenously over one hour. For herpes encephalitis or immunocompromised patients, higher doses are prescribed. Strict adherence to infusion protocols minimizes risks of renal toxicity and neurological side effects like confusion or seizures.

Common adverse effects include nausea, phlebitis, and reversible liver enzyme elevations. Storage requires temperatures between 15°C–25°C, protected from light. Concomitant use with probenecid or diuretics in elderly patients necessitates dose adjustments due to altered pharmacokinetics.

Pregnant or lactating women should use Acyvir IV only if benefits outweigh fetal risks. Overdose management includes hydration and hemodialysis to prevent renal crystal formation. Explore Acyclovir alternatives for non-severe cases or oral therapy options.

Adults: 5 mg/kg every 8 hours for HSV, 10 mg/kg for encephalitis. Pediatric dose: 250-500 mg/m² BSA. Administer via IV Infusion over ≥1 hour. Renal impairment requires dose adjustment: CrCl 25-50 ml/min – every 12 hours; CrCl <10 ml/min – 50% dose. Treatment duration typically 7-14 days based on response.

Some infrequent adverse reactions are lethargy, obtundation, tremors, confusion, hallucinations, agitation, somnolence, psychosis, convulsions and coma, phlebitis, nausea, vomiting, reversible increases in liver-related enzymes, pruritus, urticaria, rashes, increases in blood urea and creatinine. Local inflammatory reactions may occur if Acyvir IV Infusion is inadvertently infused into extracellular tissues.

Pregnancy Category B. Use only if potential benefit justifies risk. Excreted in breast milk – decide whether to discontinue nursing or drug.

Must administer as slow IV infusion (≥60 minutes). Maintain adequate hydration. Monitor renal function and neurological status. Caution in patients with CNS disorders or electrolyte imbalances.

Pediatrics: Dose based on BSA (250-500 mg/m²). Geriatrics: Reduce dose due to likely renal impairment. Renal impairment: Adjust dosing interval per CrCl – 12-24 hour intervals for CrCl <50 ml/min.

Overdosage of intravenous Acyvir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with over dosage. Adequate hydration is essential to reduce the possibility of crystal formation in the urine. Hemodialysis significantly enhances the removal of Acyvir from the blood and may, therefore, be considered an option in the management of overdose of Acyvir.